TEMPUS ARIES: A Biobank Registry Platform Study in Oncology
← catalyst calendarNCT06207032 · readout in 1,016 d
Sponsored by Tempus AI (industry) · TEM — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
500estimated
Sites
32
Countries
Puerto Rico, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-26 | actual | When the study began enrolling |
| Primary completion | 2029-06-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-06-01 | estimated | The whole study's end, after follow-up |
| First posted | 2024-01-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Cancer
Primary outcome
what the primary-completion date above is the date OFChanges in ctDNA from baseline, on-treatment and post-treatment blood samples.
measured 5 years
Publications
- PMID 29968853 — cited as background
- PMID 36796877 — cited as background
- PMID 31040929 — cited as background
- PMID 31570899 — cited as background
- PMID 34215841 — cited as background
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · TEM's whole pipeline · Catalyst calendar · Every registered study · What changed